The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biotech startup archon biosciences aims to revolutionize antibody drug design
Archon Biosciences, a biotech startup co-founded by Nobel Prize winner David Baker, focuses on computational protein design to enhance biologic drugs through innovative "antibody cages." Launched with $20 million in seed funding, the company aims to improve antibody properties while minimizing changes to their structure. With plans for clinical trials and a financial runway into 2026, Archon is poised to make significant advancements in drug development.